Blau Farmacêutica (BLAU3) Q1 2025 earnings summary

Executive summary

• Net revenue grew 4% year-over-year to BRL 373 million in Q1 2025, driven by strong private hospital segment growth of 15%, while retail, aesthetics, and plasma segments declined 24% due to temporary factors.

• Recurring net income increased 50% year-over-year to BRL 63 million, with reported net income up 129% to BRL 91 million, boosted by a one-time gain from the sale of a botulinum toxin registration.

• Gross margin expanded 680 bps to 40.1%, marking the sixth consecutive quarter of improvement, and recurring EBITDA rose 28% to BRL 83 million.

• Investments in biotechnology, production capacity, and R&D rose 55% to BRL 73 million, with a focus on monoclonal antibodies and plant expansion.

• Dividend of BRL 45 million declared for tax efficiency; leverage reduced to 0.2x, reflecting strong financial health.

Financial highlights

• Net revenue: BRL 373 million (+4% YoY); private hospital revenue +15%, public -5%, retail/aesthetics/plasma -24%.

• Gross margin: 40.1% (+680 bps YoY); recurring EBITDA: BRL 83 million (+28% YoY); margin: 22.2% (+420 bps YoY).

• Recurring net income: BRL 63 million (+50% YoY); reported net income: BRL 91 million (+129% YoY).

• CAPEX: BRL 73 million (+55% YoY), mainly for biotechnology and capacity expansion.

• Net debt: BRL 67 million (down 43% YoY); leverage at 0.2x EBITDA.

Outlook and guidance

• Management expects normalization in retail, aesthetics, and plasma segments in 2Q25, with continued strong growth in the private hospital segment.

• Long-term prospects remain positive, supported by capacity expansion, new product launches, and international expansion, with a pipeline of BRL 3 billion in products submitted to ANVISA.

• Monoclonal antibody launches could double incremental TAM to BRL 6 billion between 2028 and 2030.